Kiniksa Raises ARCALYST Revenue Guidance to $930M-$945M on Strong Q1 Performance
KNSA has more than doubled off its 52-week low of $20.19 on elevated volume (2.0× avg).
Summary
Kiniksa Pharmaceuticals reported robust first-quarter 2026 financial results, with ARCALYST net product revenue surging 56% year-over-year to $214.3 million and net income rising to $22.6 million. Crucially, the company raised its full-year 2026 ARCALYST net product revenue guidance to $930-$945 million, an increase from the prior $900-$920 million range. This upward revision signals stronger-than-anticipated commercial momentum for their key product, which is a significant positive catalyst for the stock. The company also noted an increased cash balance of $468.1 million and confirmed KPL-387 Phase 2 data is expected in the second half of 2026. Investors will now focus on continued ARCALYST sales execution and the upcoming pipeline data.
At the time of this announcement, KNSA was trading at $46.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.4B. The 52-week trading range was $20.19 to $50.03. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.